Ezetimibe for primary hypercholesterolemia
References
Additional references
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA 2002;288(23):2998‐3007. [0098‐7484 (Print)]
Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low‐density lipoprotein cholesterol goals with five statins. The American Journal of Medicine 2001;111(3):185‐91. [0002‐9343 (Print)]
Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. American Journal of Epidemiology 2004;160(5):421‐9. [0002‐9262 (Print)]
Bustos C, Hernandez‐Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG‐CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. Journal of the American College of Cardiology 1998;32(7):2057‐64. [0735‐1097 (Print)]
Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256(20):2835‐8. [0098‐7484 (Print)]
Catapano A, Brady WE, King TR, Palmisano J. Lipid altering‐efficacy of ezetimibe co‐administered with simvastatin compared with rosuvastatin: a meta‐analysis of pooled data from 14 clinical trials. Current Medical Research and Opinion 2005;21(7):1123‐30. [0300‐7995 (Print)]
Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303(6797):276‐82. [0959‐8138 (Print)]
Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clinical Chemistry and Laboratory Medicine 2005;43(8):793‐801. [1434‐6621 (Print)]
Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37‐46.
De Backer G, Ambrosioni E, Borch‐Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal 2003;24(17):1601‐10. [0195‐668X (Print)]
Deeks J, Higgins JPT, Altman D, editors. Analysing and presenting results. In: Alderson P, Green S, Higgins JPT editor(s). Cochrane Reviewers' Handbook 4.2.1. Chichester, UK: John Wiley & Son, Ltd., 2003.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88.
Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998;352(9143):1801‐7. [0140‐6736 (Print)]
Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360(9343):1347‐60. [0140‐6736 (Print)]
Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97(10):946‐52. [0009‐7322 (Print)]
Green S, Deeks J, Savio F. Meta‐analysis of continuous data: does the end justify the mean?. 9th International Cochrane Colloquium Abstracts; 2001 October 9‐13; France. Lyon, France, 2001:Abstract no 1:pa003. [Abstract no 1:pa003]
Grundy SM. Cholesterol and coronary heart disease. A new era. JAMA 1986;256(20):2849‐58. [0098‐7484 (Print)]
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227‐39. [1524‐4539 (Electronic)]
Hearst N, Grady D, Barron HV, Kerlikowske K. Reserching Using Existing Data: Secondary Data Analysis, Ancillary Studies, and Systematic Reviews. In: Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB editor(s). Designing Clinical Research. 2nd Edition. Philadelphia, USA: Lippincott Williams & Wilkins, 2001.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analysis. BMJ 2003;327:557‐60.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002;360(9326):7‐22. [0140‐6736 (Print)]
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol‐lowering with simvastatin in 5963 people with diabetes: a randomised placebo‐controlled trial. Lancet 2003;361(9374):2005‐16. [1474‐547X (Electronic)]
Husereau DR. Ezetimibe for lowering blood cholesterol. Issues in Emerging Health Technologies 2003;49:1‐4. [1488‐6324 (Print)]
Hutter CM, Austin MA, Humphries SE. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. American Journal of Epidemiology 2004;160(5):430‐5. [0002‐9262 (Print)]
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [0197‐2456 (Print)]
Kosoglou T, Statkevich P, Johnson‐Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clinical Pharmacokinetics 2005;44(5):467‐94. [0312‐5963 (Print)]
Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid‐lowering effects on endothelial function in humans. Circulation 2005;111(18):2356‐63. [1524‐4539 (Electronic)]
Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 1994;308(6925):367‐72. [0959‐8138 (Print)]
Mantel N, Haenzel W. Statiatical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22:719‐48.
McKenney JM. Pharmacologic options for aggressive low‐density lipoprotein cholesterol lowering: benefits versus risks. The American Journal of Cardiology 2005;96(4A):60E‐66E. [0002‐9149 (Print)]
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta‐analyses. Lancet 1999;354(9193):1896‐900.
National Cholesterol Education Program (NCEP) Expert Panel on Detection et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Archives of Internal Medicine 1988;148(1):36‐69. [0003‐9926 (Print)]
National Cholesterol Education Program (NCEP) Expert Panel on Detection et al. Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486‐97. [0098‐7484 (Print)]
Patel SB. Ezetimibe: a novel cholesterol‐lowering agent that highlights novel physiologic pathways. Current Cardiology Reports 2004;6(6):439‐42. [1523‐3782 (Print)]
Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L‐TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid‐lowering therapy and achieving low‐density lipoprotein cholesterol goals. Archives of Internal Medicine 2000;160(4):459‐67. [0003‐9926 (Print)]
Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid‐lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348(9024):387‐8. [0140‐6736 (Print)]
Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA‐HIT: a randomized controlled trial. JAMA 2001;285(12):1585‐91. [0098‐7484 (Print)]
Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31(1):150‐3. [0300‐5771 (Print)]
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711‐8. [0098‐7484 (Print)]
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine 1995;333(20):1301‐7. [0028‐4793 (Print)]
Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256(20):2823‐8. [0098‐7484 (Print)]
Sterne JAC, Bradburn MJ, Egger M. Meta‐analysis in Stata(TM). In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Healt Care. 2nd Edition. London: BMJ Publication Group, 2001.
Vaughan CJ. Prevention of stroke and dementia with statins: Effects beyond lipid lowering. The American Journal of Cardiology 2003;91(4A):23B‐29B. [0002‐9149 (Print)]
Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long‐term coronary heart disease mortality in different cultures. Twenty‐five‐year follow‐up of the seven countries study. JAMA 1995;274(2):131‐6. [0098‐7484 (Print)]
Wang TD, Chen WJ, Chien KL, Seh‐Yi Su SS, Hsu HC, Chen MF, et al. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. The American Journal of Cardiology 2001;88(7):737‐43. [0002‐9149 (Print)]
Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. The New England Journal of Medicine 2000;342(2):101‐14. [0028‐4793 (Print)]
